Mirae Asset Global Etfs Holdings Ltd. Viridian Therapeutics, Inc.\De Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $41.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 34,410 shares of VRDN stock, worth $669,274. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,410
Previous 31,490
9.27%
Holding current value
$669,274
Previous $409,000
91.2%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VRDN
# of Institutions
178Shares Held
76.6MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$92.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$86 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$75.5 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$73 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$67 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $776M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...